Zobrazeno 1 - 10
of 812
pro vyhledávání: '"Baohui HAN"'
Autor:
Cuicui Zhang, Tianqing Chu, Qiming Wang, Ying Cheng, Yongxiang Zhang, Ruili Wang, Leilei Ma, Chaonan Qian, Baohui Han, Kai Li
Publikováno v:
Cancer Biology & Medicine, Vol 21, Iss 10, Pp 951-962 (2024)
Objective: The possible enhancing effect of anlotinib on programmed death receptor ligand (PD-L1) antibody and the efficacy-predicting power of PD-L1 in micro-conduit endothelium, including lymphatic endothelial cells (LECs) and blood endothelial cel
Externí odkaz:
https://doaj.org/article/d754edaea9854a43b356190d79df6e47
Autor:
Aimi Huang, Fuchuang Zhang, Jiyang Zhang, Xiaoya Xu, Zhikuan Li, Sheng Chen, Baoning Nian, Dadong Zhang, Baohui Han, Aiqin Gu, Weimin Wang
Publikováno v:
Cancer Nanotechnology, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Background Anlotinib is a targeted therapy indicated for some malignancies, including advanced non-small cell lung cancer (NSCLC). However, noninvasive biomarkers for identifying patients who will benefit from this disease remain lacking. Me
Externí odkaz:
https://doaj.org/article/c33f84d83b864a669b908d652c95d6bd
Publikováno v:
Cancer Biology & Therapy, Vol 25, Iss 1 (2024)
ABSTRACTBackground To investigate the influence of pretreatment neutrophil-to-lymphocyte ratio (NLR) and procalcitonin (PCT) on progression-free survival (PFS) in extensive-stage small-cell lung cancer (SCLC) patients.Method A total of 100 extensive-
Externí odkaz:
https://doaj.org/article/f3a06a72f2b0482e968a27edbe10359e
Autor:
Hongyu Liu, Chao Zhou, Haohua Jiang, Tianqing Chu, Runbo Zhong, Xueyan Zhang, Yinchen Shen, Baohui Han
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundChemotherapy combined with PD-1 inhibitor treatment has revolutionized the standard of care for patients with NSCLC. However, the benefit is not universal, highlighting the need for precise prediction factors. Given their relationship with
Externí odkaz:
https://doaj.org/article/acb93639fc344a28be27933120519743
Autor:
Bo Zhang, Hongyu Liu, Chunlei Shi, Zhiqiang Gao, Runbo Zhong, Aiqin Gu, Tianqing Chu, Huimin Wang, Liwen Xiong, Wei Zhang, Xueyan Zhang, Bo Yan, Jiajun Teng, Weimin Wang, Hao Bai, Rong Qiao, Lei Cheng, Yanbin Kuang, Ruiying Zhao, Hua Zhong, Baohui Han
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Resistance to immune checkpoint inhibitors (ICIs) represents a major unmet medical need in non-small cell lung cancer (NSCLC) patients. Vascular endothelial growth factor (VEGF) inhibition may reverse a suppressive microenvironmen
Externí odkaz:
https://doaj.org/article/fd0c3fa6cd7f420a97190e5951f015d2
Autor:
Liang Zheng, Fang Hu, Wei Nie, Jun Lu, Bo Zhang, Jianlin Xu, Shuyuan Wang, Ying Li, Xiaoxuan Zheng, Wei Zhang, Yinchen Shen, Runbo Zhong, Tianqing Chu, Baohui Han, Hua Zhong, Xueyan Zhang
Publikováno v:
Cancer Medicine, Vol 13, Iss 17, Pp n/a-n/a (2024)
Abstract Background The 9th edition of the TNM Classification for lung cancer delineates M1c into two subcategories: M1c1 (Multiple extrathoracic lesions within a single organ system) and M1c2 (Multiple extrathoracic lesions involving multiple organ
Externí odkaz:
https://doaj.org/article/5c7af439f5194ea8b098e0278cb05b37
Autor:
Yanwei Zhang, Beibei Sun, Yinghong Yu, Jun Lu, Yuqing Lou, Fangfei Qian, Tianxiang Chen, Li Zhang, Jiancheng Yang, Hua Zhong, Ligang Wu, Baohui Han
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-6 (2024)
Abstract This research explores the potential of multimodal fusion for the differential diagnosis of early-stage lung adenocarcinoma (LUAD) (tumor sizes < 2 cm). It combines liquid biopsy biomarkers, specifically extracellular vesicle long RNA (evlRN
Externí odkaz:
https://doaj.org/article/4c9b857922374136bc2311cb7ee08835
Autor:
Yunhui Qu, Xiuzhi Zhang, Rong Qiao, Feifei Di, Yakang Song, Jun Wang, Longtao Ji, Jie Zhang, Wanjian Gu, Yifei Fang, Baohui Han, Rongxi Yang, Liping Dai, Songyun Ouyang
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-15 (2024)
Abstract Background Non-small cell lung cancer (NSCLC) accounts for the vast majority of lung cancers. Early detection is crucial to reduce lung cancer-related mortality. Aberrant DNA methylation occurs early during carcinogenesis and can be detected
Externí odkaz:
https://doaj.org/article/b8003d956a4148b8bfd7804c4e7e85d1
Autor:
Jun Lu, Ying Li, Wei Zhang, Hua Zhong, Fang Hu, Liang Zheng, Xiaohua Yang, Lin Huang, Xueyan Zhang, Tianqing Chu, Baohui Han, Yinchen Shen, Wei Nie, Jianlin Xu, Shuyuan Wang, Runbo Zhong, Xiaoxuan Zheng
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
Background Combining immune checkpoint inhibitors (ICIs) with chemotherapy has become a standard treatment for patients with non-small cell lung cancer (NSCLC) lacking driver gene mutations. Reliable biomarkers are essential for predicting treatment
Externí odkaz:
https://doaj.org/article/b9a445ffb44c4e5997bab417d9a49d00
Autor:
Bo Zhang, Hua Zhong, Chunlei Shi, Zhiqiang Gao, Runbo Zhong, Aiqin Gu, Weimin Wang, Tianqing Chu, Liwen Xiong, Wei Zhang, Huimin Wang, Xueyan Zhang, Baohui Han
Publikováno v:
The Clinical Respiratory Journal, Vol 17, Iss 12, Pp 1361-1367 (2023)
Abstract Introduction Durvalumab is a check‐point inhibitor against programmed death ligand‐1 (PD‐L1), and anlotinib is a new orally administered multitarget tyrosine kinase inhibitor (TKI). Both agents have been approved in China. Preclinical
Externí odkaz:
https://doaj.org/article/a5f8528abb824329a4d37c54d296c13e